High-dose inhaled nitric oxide (iNO) therapy may improve oxygenation and reduce the risk of ARDS-related mortality among critically ill Black patients with COVID-19, according to a first-of-its-kind study published in the American Journal of Respiratory and Critical Care Medicine.
High-dose inhaled nitric oxide led to more rapid weaning from supplemental oxygen and reduced length of hospital stay in pregnant women hospitalized with severe COVID-19 pneumonia, according to a study published in Obstetrics & Gynecology.
Beyond Air Inc will initiate a clinical study of its LungFit tankless nitric oxide (NO) system for evaluation of the safety and efficacy of high concentration inhaled NO given intermittently to adults hospitalized with acute viral pneumonia, including SARS-CoV-2.
This clinical trial will monitor patients with mild to moderate cases of COVID-19 to see how they respond to inhaled nitric oxide as a treatment.
Read More
Bellerophon submits new drug application for INOpulse inhaled nitric oxide therapy to treat COVID-19 patients receiving oxygen.
Read More
The patient was treated under an emergency IND filed by a qualified Investigator and approved by the US FDA, according to the manufacturer Vero Biotech.
Read More
Bellerophon Therapeutics will soon initiate a Phase 3 trial for its INOpulse inhaled nitric oxide therapy for the treatment of pulmonary hypertension associated with pulmonary fibrosis.
Read More
The FDA has approved the Genosyl inhaled nitric oxide (iNO) gas delivery system, a tankless, portable iNO system that eliminates the need for large nitric oxide tanks.
Read More
Circassia Pharmaceuticals is acquiring exclusive commercialization rights to nitric oxide product AirNOvent in the US and China from from AIT Therapeutics.
Read More
Inhaled nitric oxide had significant antibacterial activity against Mycobacterium abscessus (M. abscessus), which can infect the airways of patients with cystic fibrosis.
Read More
RTs may find it difficult to choose between available inhaled pulmonary vasodilators (IPVs)—inhaled nitric oxide or nebulized epoprostenol—to treat pulmonary hypertension.
Read More
Preterm infants born younger than 29 weeks’ gestational age who were treated for pulmonary...
Read More
A new compound developed by researchers from Spain allows for the detection of nitric oxide by fluorescence.
Read More
Low levels of both oxygen and nitric oxide appear to have an unfortunate synergy for patients with sickle cell disease, researchers report.
Read More
Inhaled nitric oxide might be an alternative to more invasive, costlier ECMO.
Read More